Revista de vasculitis

Cutaneous Small Vessel Vasculitis Due to Dolutegravir: A Rare Side Effect of Dolutegravir Based HAART Regimen in PLHIV

Abstract

Cutaneous small-vessel vasculitis, Efavirenz-resistant virus, Cutaneous examination, Leukocytoclastic vasculitis

According to World Health Organization (WHO), Dolutegravir-based regimen is considered as first-line therapy for PLHIV and strongly recommended for all adults and children at the 10th International AIDS Society Conference on HIV Science (IAS 2019) held in Mexico City. Dolutegravir (integrase inhibitor) is pharmacokinetically favorable with a single daily dose, fewer drug interactions, superior potency against HIV-1, and potency against efavirenz-resistant virus. In 2020, NACO announced the phase-wise replacement of TLE regimen to TLD regimen.